Specific treatment modalities for elderly patients with chronic lymphocytic leukemia

Author:

Michallet Anne-Sophie12,Feugier Pierre2,Delmer Alain2,Ysebaert Loic2,Cazin Bruno2,Dartigeas Caroline2,Fornecker Luc2,Van de Neste Eric2,Cymbalista Florence2,Lévy Vincent2,Leblond Veronique2,Troussard Xavier2

Affiliation:

1. CHLS, Department of Hematology, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.

2. Subcommittee on Elderly CLL Patients on behalf of the Intergroupe Français de la LLC et du GOELAMS, APHP-Groupe Hospitalier la Pitié Salpétrière, 47–83 Bd de l’Hôpital, 75651 Paris Cedex 13, France

Abstract

To date, the majority of trials on chronic lymphocytic leukemia (CLL) have focused on patients considerably younger than the median age of onset for CLL. As a result, no definitive treatment exists for elderly patients, especially less medically fit patients. Even today, most physicians consider chlorambucil to be an appropriate option for elderly CLL patients. Practices, however, have subsequently changed following the results of several Phase III trials. Given the potential of these new immunotherapy regimens, selecting the right treatment for elderly CLL patients is still challenging.

Publisher

Future Medicine Ltd

Subject

Geriatrics and Gerontology,General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3